Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256759 · ClinicalTrials.gov registry record · Phase 2
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04256759: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04256759 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04256759, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
Interventions
- DRUG Dupilumab 300Mg Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04256759
The ClinicalTrials.gov registry entry for NCT04256759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab 300Mg Solution for Injection is the first listed.
NCT04256759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04256759 about?
NCT04256759 is a clinical study titled "Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus". To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
What is the current status of trial NCT04256759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-01. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT04256759?
The interventions under investigation include: Dupilumab 300Mg Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT04256759?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.